An interventional study of IMDENDRIM in Efficacy and Safety, sponsored by French Association for the Advancement Medical Research. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-21.
Sponsored by French Association for the Advancement Medical Research · Not applicable, Interventional, and Treatment
Objective (s) : To Evaluate the efficacy and safety of Treatment of non-responding to conventional therapy inoperable liver cancers by in situ introduction of ImDendrim.
Trial Design:
An, open-labeled and unicenter study in women or men with primary hepatocellular cancer or metastatic liver without standard therapeutic options for treatment including chemotherapy or surgery.
Objective (s) : To Evaluate the efficacy and safety of Treatment of non-responding to conventional therapy inoperable liver cancers by in situ introduction of ImDendrim "[188Re] rhenium complex coupled to a imidazolic ligand and associated with a dendrimer".
Trial Design:
Type of the clinical Trial:
An, open-labeled and unicenter study in women or men with primary hepatocellular cancer or metastatic liver without standard therapeutic options for treatment including chemotherapy or surgery.
Exclusion Criteria:
Device: IMDENDRIM
In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
size of tumor
evaluation criteria for solid tumors RECIST
Time frame: 12 weeks
Progression free survival PFS
PFS-end-point was defined as either Imaging progression or death of any cause
Time frame: 12 weeks
HPFS
Hepatic free survival
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.